Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sagimet Biosciences (Nasdaq: SGMT) said management will participate in three investor conferences in early March 2026: TD Cowen on March 2 (Boston), Leerink on March 9 (Miami) and Citizens Life Sciences on March 10 (Miami).
TD Cowen and Leerink fireside chats will be webcast and archived for 90 days on the company's investor site.
Details
News Market Reaction – SGMT
On Feb 25, the day this news came out, SGMT closed 3.55% above the previous close.
Data tracked by StockTitan Argus for the Feb 25 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN MATEO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in three upcoming investor conferences.
- TD Cowen 46th Annual Health Care Conference in Boston, MA, on March 2, 2026, with a fireside chat at 1:10pm ET (link here).
- Leerink Global Healthcare Conference in Miami, FL, on March 9, 2026, with a fireside chat at 1pm ET (link here).
- The Citizens Life Sciences Conference in Miami, FL, on March 10, 2026, with a fireside chat at 10:45am ET.
The TD Cowen and Leerink fireside chats will be available in the Investors & Media section of Sagimet’s website at www.sagimet.com, with an archived replay available for 90 days following the live event.
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. Denifanstat, an oral, once-daily pill, met all primary endpoints in its Phase 2b FASCINATE-2 clinical trial in MASH as well as all primary and secondary endpoints in Sagimet’s license partner for China’s Phase 3 clinical trial in moderate-to-severe acne. A combination of denifanstat and resmetirom is currently being tested in a Phase 1 PK clinical trial and is planned to be developed for cirrhotic patients living with F4-stage MASH. TVB-3567, a second oral FASN inhibitor which is planned to be developed for acne, is currently being tested in a Phase 1 first-in-human clinical trial. For additional information about Sagimet, please visit www.sagimet.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
JAllaire@LifeSciAdvisors.com
Media Contact:
Maggie Whitney
LifeSci Communications
mwhitney@lifescicomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.